U.S. markets closed
  • S&P Futures

    4,354.00
    +36.25 (+0.84%)
     
  • Dow Futures

    34,278.00
    +235.00 (+0.69%)
     
  • Nasdaq Futures

    14,168.50
    +181.75 (+1.30%)
     
  • Russell 2000 Futures

    1,938.80
    +10.50 (+0.54%)
     
  • Crude Oil

    87.17
    +0.56 (+0.65%)
     
  • Gold

    1,797.50
    +4.40 (+0.25%)
     
  • Silver

    22.79
    +0.11 (+0.50%)
     
  • EUR/USD

    1.1157
    +0.0010 (+0.09%)
     
  • 10-Yr Bond

    1.8070
    -0.0410 (-2.22%)
     
  • Vix

    30.49
    -1.47 (-4.60%)
     
  • GBP/USD

    1.3401
    +0.0019 (+0.14%)
     
  • USD/JPY

    115.4110
    +0.1090 (+0.09%)
     
  • BTC-USD

    36,976.71
    +907.12 (+2.51%)
     
  • CMC Crypto 200

    836.43
    +16.93 (+2.07%)
     
  • FTSE 100

    7,554.31
    +84.53 (+1.13%)
     
  • Nikkei 225

    26,720.06
    +549.76 (+2.10%)
     

EXCLUSIVE: Pasithea Administers First IV Ketamine Infusion Therapy In Depression Patients

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • KTTA

Pasithea Therapeutics Corp's (NASDAQ: KTTA) wholly-owned subsidiary, Pasithea Clinics, has administered intravenous (IV) ketamine therapy to its first patients with treatment-resistant depression.

Pasithea Clinics commenced IV ketamine infusion therapy in Knightsbridge, London.

In sub-anesthetic doses, ketamine has shown efficacy and a rapid and sustained effect in some psychiatric disorders, such as treatment-resistant depression and post-traumatic stress disorder.

Ketamine is an FDA-approved anesthetic and was introduced over 50 years ago. It has recently been repurposed in significantly lower doses to treat psychiatric disorders.

Pasithea has clinical partnerships to administer its IV ketamine treatment. In the U.K., Pasithea has partnered with ZEN Healthcare – a network of health clinics in London.

In the U.S., it has partnered with The IV Doc Inc to provide in-home IV ketamine infusions.

Related: EXCLUSIVE: Pasithea Therapeutics Launches First Ketamine Clinic In The UK.

Price Action: KTTA shares closed 1.50% higher at $2.71 on Tuesday.

Photo: Michaelberry via Wikimedia

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.